GLP-1 side effects in the published literature
Understanding the documented adverse events from GLP-1 clinical trials is part of making an informed decision. Here’s what the data shows.
TL;DR
- Gastrointestinal effects — nausea, vomiting, diarrhea, constipation — are the most commonly reported adverse events across GLP-1 clinical trials and are usually dose-dependent.
- Rarer but more serious events including pancreatitis and gallbladder disease are documented in both the trial literature and FDA labeling.
- Most common GI side effects appear in early weeks of titration and tend to diminish over time, though individual response varies significantly.
What it is
Side effects in GLP-1 receptor agonist therapy refers to the documented adverse events reported by participants in controlled clinical trials and captured in FDA prescribing information. These are distinct from anecdote or informal reports — they represent systematically collected safety data from thousands of participants across programs including the STEP (semaglutide) and SURMOUNT (tirzepatide) trial series. Understanding this data means distinguishing between commonly reported events, which are expected and generally manageable, and rare but serious events, which require prompt clinical attention if they occur.
How it works
The GI side effect profile of GLP-1 receptor agonists is mechanistically related to the drug’s action: slowing gastric emptying and reducing gut motility can directly produce nausea, fullness, and altered bowel patterns. The dose-dependence of these effects is well-established in the published literature — higher doses are associated with higher rates of GI adverse events, which is part of the rationale for the gradual titration schedules used in clinical protocols. The central appetite-suppression effects can also contribute to reduced food intake in ways that interact with digestive function.
Who asks about it
People come to this topic in two situations: before starting therapy, wanting to understand what they’re likely to experience, and after starting, wanting to understand whether what they’re experiencing is expected and documented. Both are legitimate uses of the published information. Knowing what the literature describes does not replace clinical guidance — it supplements it.
What the research says
Across the STEP 1–4 trial program for semaglutide 2.4 mg weekly, GI adverse events were the most commonly reported side effects. In STEP 1, approximately 74% of participants in the semaglutide group reported any GI adverse event compared to approximately 48% in the placebo group. The most frequently reported events were nausea (44% vs. 16%), diarrhea (30% vs. 16%), vomiting (24% vs. 6%), and constipation (24% vs. 11%). The majority were reported as mild to moderate in severity. Injection-site reactions were also reported.
Rarer but more serious events include acute pancreatitis, which is listed in the FDA prescribing information as a risk requiring clinical attention if symptoms develop, and gallbladder events — including cholelithiasis and cholecystitis — which occurred at higher rates in the semaglutide group in STEP trials compared to placebo. The FDA label also includes a boxed warning regarding thyroid C-cell tumors based on animal studies, with the clinical significance in humans not established; the labeling notes that semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
What to know before considering it
Side effect experience varies by individual, dose, and titration rate. Any GLP-1 therapy requires a licensed clinician evaluation. Patients should discuss their complete medical history — including gallbladder history, pancreatic history, and personal or family history of thyroid conditions — with their prescribing clinician before starting. Compounded GLP-1 formulations are prepared by state-licensed 503A pharmacies from FDA-approved active pharmaceutical ingredients and are not themselves FDA-approved.
The Halftime POV
A complete picture of the risk profile is not a reason to avoid a conversation — it’s the conversation. The STEP trial side effect data is publicly available, published in major peer-reviewed journals, and referenced in FDA prescribing information. Reading it shouldn’t be alarming; it should be clarifying. People who understand what the literature documents are better equipped to recognize what’s expected, what’s worth flagging to their clinician, and what warrants urgent attention.
Related reading:
FAQ
Q: What are the most common GLP-1 side effects? A: The STEP trial series documented nausea, vomiting, diarrhea, and constipation as the most commonly reported adverse events — typically highest during dose escalation. In STEP 1, approximately 44% of participants reported nausea and 25% reported vomiting. Most gastrointestinal effects were described as mild to moderate in severity.
Q: What are the more serious adverse events documented in GLP-1 trials? A: Published trial data documents pancreatitis, gallbladder disease (including cholelithiasis), and potential thyroid C-cell effects as more serious but less common events. The published contraindications include personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
Q: Do GLP-1 side effects improve over time? A: Published literature describes most gastrointestinal side effects as most pronounced during initial dose escalation, with many participants reporting improvement as the body adjusts. Dose escalation protocols are designed in part to manage this — slower escalation is associated with better tolerability in clinical practice.
Disclaimer
This article is educational and is not medical advice. Compounded GLP-1 medications are prepared by state-licensed 503A compounding pharmacies from FDA-approved active pharmaceutical ingredients and are not themselves FDA-approved. GLP-1 therapies are available only with a valid prescription following a licensed clinician evaluation. Clinical outcomes depend on individual factors including baseline health, adherence, diet, and physical activity. Individual results vary. Side effects are common and may include nausea, injection-site reactions, and gastrointestinal symptoms. Halftime Health is launching soon — join the waitlist to get updates.
Note on ongoing litigation: Compounded GLP-1 products are the subject of ongoing litigation (Novo Nordisk v. Hims & Hers, Feb. 2026). The regulatory landscape for compounded GLP-1 formulations continues to evolve.
Get updates
Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.
Sources
- Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” NEJM, 2021 (STEP 1) — adverse events table
- FDA. Wegovy (semaglutide) Prescribing Information, including boxed warning and contraindications. 2023
- Davies M, et al. “Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2).” The Lancet, 2021
